

**CENGILD MEDICAL BERHAD**  
**202101004143 (1404442-P)**  
(Incorporated in Malaysia)

**MINUTES OF THE EXTRAORDINARY GENERAL MEETING (“EGM”) OF THE COMPANY  
CONDUCTED THROUGH LIVE STREAMING FROM THE BROADCAST VENUE AT TRICOR  
BUSINESS CENTRE, MANUKA 2 & 3, UNIT 29.01 LEVEL 29, TOWER A, VERTICAL  
BUSINESS SUITE, AVENUE 3, BANGSAR SOUTH, NO. 8, JALAN KERINCHI, 59200 KUALA  
LUMPUR ON MONDAY, 13 MAY 2024, AT 3.00 P.M.**

---

Present at Broadcast Venue	:	Dato’ Dr. Tan Huck Joo	Executive Chairman
		Dr. Mohamed Akhtar Bin Mohamed Ditali Qureshi	Executive Director
		Mr. Kua Choo Kai	Independent Non-Executive Director
		Dr. Azrina Binti Abu Bakar	Independent Non-Executive Director
		Dr. Chong Su Lin	Independent Non-Executive Director
		Ms. Yap Soh Kim	Acting Chief Executive Officer
		Mr. Tee Thiam Chai	Company Secretary
In Attendance (as per Attendance List)	:	Ms. Cheah Wen Lih (via video conferencing)	Financial Controller
		Ms. Wendy Teh (via video conferencing)	Representative from Hong Leong Investment Bank Berhad
		Surveyor C.Y. Lim (via video conferencing)	} Representatives from City Valuers and Consultants Sdn Bhd
		Mr Ong Eik Ren (via video conferencing)	
		Ms Aw Ee Leng (via video conferencing)	} Representatives from Messrs Teh & Lee
		Mr Clement Ong Ye Xiang (via video conferencing)	
		Mr Joe Tan Keng Chiew (via video conferencing)	Representative from Crowe Malaysia PLT

The attendance of members, corporate representatives and proxies is as per the Summary of Attendance List via Remote Participation and Voting facilities provided by Tricor Investor & Issuing House Services Sdn Bhd.

**CHAIRMAN**

The Chairman welcomed the members and attendees to the Company’s EGM. He informed that the EGM would be conducted through live streaming from Tricor Business Centre. The Chairman then introduced the Board members, Company Secretary, Senior Management and Principal Advisers to the shareholders.

**NOTICE**

The notice convening the meeting, having been circulated earlier to all members of the Company and advertised in the National Daily newspaper within the prescribed period, was taken as read.

**QUORUM**

The Chairman informed the meeting that the Constitution of the Company required the presence of at least two members or proxies or corporate representatives to form a quorum. For a virtual general meeting, the quorum shall be determined by the number of members who logged-in at commencement of the meeting.

The Chairman informed the quorum requirement had been met at the start of the meeting and called the meeting to order.

**ANNOUNCEMENT ON ADMINISTRATIVE MATTERS**

The Chairman informed that pursuant to Rule 8.31A of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad, all resolutions set out in the notice of a general meeting must be voted by poll. The poll would be conducted after the items on the agenda have been dealt with.

The Chairman then briefed the shareholders on the flow of the meeting.

The poll administrator was Tricor Investor & issuing House Services Sdn Bhd and the independent scrutineer was Asia Securities Sdn Bhd.

**ORDINARY RESOLUTION 1**

**PROPOSED ACQUISITION OF A STRATIFIED PROPERTY WITH A COMBINED STRATA FLOOR AREA OF 100,442 SQUARE FEET TOGETHER WITH AT LEAST 182 CARPARK BAYS FORMING PART OF A PURPOSE-BUILT PRIVATE MEDICAL CENTRE TO BE ERECTED ON A PARCEL OF LEASEHOLD LAND HELD UNDER PAJAKAN NEGERI 46331, LOT 58194, MUKIM AND DAERAH KUALA LUMPUR, WILAYAH PERSEKUTUAN KUALA LUMPUR FOR A CASH CONSIDERATION OF RM122,340,668 (“PROPOSED ACQUISITION”)**

The Chairman informed that the details on the Proposed Acquisition were set out in the Circular to Shareholders dated 26 April 2024.

The Chairman put the following motion to the meeting for consideration:-

“THAT subject to fulfilment of the conditions precedent and the approvals of all relevant authorities and/or parties being obtained, approval be and is hereby given to Cengild Sdn Bhd (“Cengild”), a wholly-owned subsidiary of the Company, to proceed with, carry out and implement the Proposed Acquisition, in accordance with the terms and conditions of the conditional sale and purchase agreement dated 29 December 2023 entered into between Cengild and Sunny Uptown Sdn Bhd.

AND THAT the Directors of the Company and/or Cengild be and are hereby authorised to sign and execute all documents, do all things and acts as may be required to give effect to the aforesaid Proposed Acquisition with full power to assent to any conditions, variations, modifications and/or amendments in any manner as may be required or permitted by any relevant authorities and to deal with all matters relating thereto and to take all such steps and do all acts and things in any manner as they may deem necessary or expedient to implement, finalise and give full effect to the Proposed Acquisition.”

#### **ORDINARY RESOLUTION 2**

#### **PROPOSED VARIATION AND EXTENSION OF TIMEFRAME FOR THE UTILISATION OF PROCEEDS RAISED FROM THE INITIAL PUBLIC OFFERING (“IPO”) OF CENGILD MEDICAL PURSUANT TO RULE 8.24 OF THE ACE MARKET LISTING REQUIREMENTS OF BURSA SECURITIES (“PROPOSED VARIATION”)**

The Chairman informed that the details on the Proposed Variation were set out in the Circular to Shareholders dated 26 April 2024.

The Chairman put the following motion to the meeting for consideration:-

“THAT subject to the passing of Ordinary Resolution 1, and the approval of the relevant authorities and/or parties being obtained, if required, for the Proposed Variation, approval be and is hereby given to the Company to vary the utilisation of the unutilised balance of proceeds raised from Company’s IPO of approximately RM60.46 million in the manner as set out in Section 2.2 of the Circular to shareholders of the Company dated 26 April 2024.

AND THAT the Directors of the Company be and are hereby authorised to take all such steps and do all acts, deeds and things to enter into any arrangements, transactions, agreements and/or undertakings and to execute, sign and deliver on behalf of the Company, all such documents as they may deem necessary, expedient and/or appropriate to implement and give full effect to and to complete the Proposed Variation with full powers to assent to any conditions, modifications, variations and/or amendments as the Directors may in their absolute discretion deem fit, necessary, expedient, appropriate and/or as may be imposed or permitted by any relevant authorities in connection with the Proposed Variation.”

#### **QUESTIONS AND ANSWERS (“Q & A”) SESSION**

The Chairman, Dr. Mohamed Akhtar Bin Mohamed Ditali Qureshi, the Executive Director of the Company and Ms. Yap Soh Kim, the acting Chief Executive Officer addressed the questions submitted prior and during the EGM.

The Q & A Session is attached hereto as “Appendix A”, shall form part of these minutes.

#### **CONDUCT OF POLL**

Having dealt with the items on the agenda, the meeting then proceeded to vote on the Resolutions by poll. The Chairman adjourned the meeting at 3.55 p.m. for the counting of votes.

-4-

**ANNOUNCEMENT OF POLLING RESULTS**

Upon completion of the counting of votes by the poll administrator and verification of the result by the scrutineer, the Chairman resumed the meeting at 4.19 p.m. for the declaration of the result of the poll.

Based on the poll result attached hereto as "Appendix B", the Chairman declared the resolutions carried.

**CLOSURE**

The Chairman thanked those present for their attendance and closed the meeting at 4.24 p.m.

**READ AND CONFIRMED**

-----  
**CHAIRMAN**

Dated:

## CENGILD MEDICAL BERHAD [202101004143 (1404442-P)]

## QUESTIONS AND ANSWERS SESSION OF THE EXTRAORDINARY GENERAL MEETING OF THE COMPANY HELD ON 13 MAY 2024

Questions	The Company's response
<b>Acquisition of New Building</b>	
<p>1. A total of RM122 million for acquiring the property. What's the subsequent estimated capital investment required for renovation and setting-up of hospital and medical equipment etc.</p>	<p>As disclosed in Section 2.1.8, page 5 of the Circular, the estimated additional financial commitment required for renovation and setting-up of the new hospital, along with acquiring medical equipment, amounts to approximately RM60 million.</p>
<p>2. What is the rationale of building another hospital in Kuala Lumpur area when Cengild already built their presence in Bangsar? The operation in Bangsar will be carried out as usual?</p>	<p>As disclosed in Section 3, page 7 of the Circular, the new hospital will provide us with more than 2.7 times of space (from 36,588 square feet to 100,442 square feet) as compared to our existing medical centre which we are currently renting from Sunny Uptown.</p> <p>After relocation to the new hospital, we do not intend to continue the tenancy at our current medical centre.</p>
<p>3. The market takes the proposed acquisition of stratified property RM122.34 mil negatively. Add up with the additional commitment of RM60 mil for renovation, fit out and equipment this will add up to RM182.34 mil. With RM133.4 mil (RM73.4 mil &amp; RM60 mil) to be financed via bank borrowings, we can expect up to RM8 mil of interest / annum (based on 6%) that would wipe off the profitability of the Group. What are the rationales for this Proposed Acquisition when it still are relatively new in the market?</p>	<p>The business requires more space for expansion. With the proposed acquisition, our space would increase by 2.7 times. Regardless of whether the company leases or purchases a new hospital, the renovation cost of RM60 million, including fittings and equipment would still be required.</p> <p>For comparison, given that the rental rate for our existing medical centre currently stands at RM4.50 per square foot and next year's rental rate will increase up to RM5.40 per square foot. Additionally, rental is expected to increase by another up to 20% in three years.</p> <p>At the revised rental rate of up to RM5.40 per square foot and based on the purchase price of RM1,200 per square foot for the new property, the rental yield is higher than the interest rate of the financing we have secured for the new building at 4.18%. Hence, it is cheaper to purchase than to lease as the implied capital value of the new property would be higher than the purchase price.</p> <p>Presently, we pay RM165,000 per month, or about RM2 million per year in rent. If we expand our space by 2.7 times, we would be paying RM5.4 million annually at the current rate. With the rental increase to RM5.40 per square foot, the</p>

	<p>annual rent of the expanded space would then rise to RM6.4 million.</p> <p>Assuming we borrow at 70% margin financing for the acquisition, which has been secured at an interest rate of 4.18%, we would borrow RM85.5 million. The estimated financing cost would be up to RM3.57 million per year, decreasing as we repay the borrowings. In comparison, we would pay RM3.57 million in financing costs, instead of RM5.4 million based on the current rental rate, or up to RM6.4 million starting next year.</p> <p>Regarding the question about being new to the market, while we may be new as a public listed company, our hospital and doctors have been established for twenty to thirty years and are by no means new. Furthermore, we are currently operating near full capacity, which is the reason for our expansion. This need for expansion is reflected in our revenue growth from last year to this year.</p>
<p><b>4. The gestation period for new hospitals typically is between three to five years. It is rather unusual for a new medical Group which commenced operations in 2017 to expand such rapidly. Due to the short operating history, its medical centre may not be well known to the general public and appealing for medical tourism. With this ambitious Proposed Acquisition, the share price is tumbling at all-time low. Please clarify on this.</b></p>	<p>Referring to our financial records, the Company has been profitable since its second year of operation. Our doctors comprise individuals with extensive tenure, many of whom are professionals within their respective fields.</p>
<p><b>5. The significant uptick in contribution would only take place by 2030. It means that for the next 7 years, the shareholders will face with period of depression due no dividend payout and depressed share price and cash flow constraints. It is better for the Group to set-up a smaller specialised medical centre that concentrate on outpatient medical care and treatments, which has low capital and operating expenditures and fixed overhead. Compete in the low blue sea than red sea. Please clarify.</b></p>	<p>The dividend policy adopted by the Company remains unchanged.</p> <p>Cengild Medical Berhad was founded not as a small, specialised outpatient medical centre, but rather concentrates on comprehensive medical care and treatments. The group has recruited the best expertise in its respective fields and established itself as a tertiary care centre. Our doctors have numerous referrals from many major private and government hospitals nationwide. In comparison with many private medical centres. Our Group is bigger in scale and scope in the field of gastroenterology.</p>

<p><b>6. If this Proposed Acquisition is passed through, it will have long-term negative bearing on its financials and debt loading, growth expansion plan and transfer to Main Market. In understanding whether the Proposed Acquisition is viable, the Group needs to be scalable by offering more services and attracting more medical talents and patients to the Group. So far, we see none as the top line and bottom line are not growing since the IPO. Kindly provide the business plan to achieve these?</b></p>	<p>The current operational capacity of our Group's existing medical centre is nearing full utilisation, with our ability to substantially scale our operations at this existing location constrained by the limited availability of suitable space within Nexus @ Bangsar South. The larger built-up area of the Property, exceeding double the size of our current medical centre, will afford our Group to ample capacity to recruit more consultants and surgeons, thereby facilitating the expansions of our operations.</p> <p>Furthermore, our financial performance highlights a profit after tax of RM10 million for the fiscal year 2021; RM9.4 million profit after tax for the year 2022 primarily attributed to listing expenses; and a profit after tax of 13.3 million for the fiscal year 2023.</p>
<p><b>7. To have a hospital set-up, it is costly to operate with gestation period of 3 to 5 years upon completion. Focus should be to build its business since it is relatively new healthcare group that was established in 2017 and still weak on its medical tourism segment i.e. less than 5% of its revenue. It envisages to grow fast but failed to attract more medical talents as just one loss of its employee consultants has impacted its revenue and profitability significantly. Please clarify on this.</b></p>	<p>Medical tourism is not our main focus, however, there is a notable emphasis in Melaka and Penang, where certain hospitals experience high foreign patient volume.</p> <p>Since the passing of Professor Goh, our medical team has been strengthened by the addition of one physician, two ENT surgeons, one urologist, one cardiologist and a full-time gastroenterologist.</p>
<p><b>8. The management team is still wobbling around about their business strategy from light to heavy. Light business model is a good strategy like in the case of Qualitas and Mediviron with high EBITDA. As a small Group with track record of 2017, it is bad strategy to commit such a high capital expenditure. Please clarify on this.</b></p>	<p>We operate a tertiary medical centre within our Group. A direct comparison with Qualitas and Mediviron is inappropriate due to the distinct segments of medical services provided. To facilitate our expansion plan, acquisition of a new building is financially advantageous in the long term as compared to leasing the new building.</p>
<p><b>9. What is the plan of the Group to assure the shareholders of the commercial viability of the Proposed Acquisition &amp; how will it elevate the Group to higher level? We know the major selling down of share price &gt;40% is to do with the shareholders' negative perceptions of this transaction and its deteriorating financials y-o-y. Please clarify on this.</b></p>	<p>The first day since IPO, the Group outlined its intentions for expansion, as included in the prospectus. The process of leasing the new space possesses several challenges, including waiting for the current tenant to vacate the place, renovating the place to accommodate a medical care centre, and complying with requirements set out by the Ministry of Health. Upon assessment, it has determined that acquiring the building would offer greater cost and operational efficiency over the long term.</p>

<p><b>10. Is the Group faces with difficulty in expansion of its medical team especially in attracting and recurring consultants and surgeons in the areas of gastroenterology and hepatology?</b></p>	<p>As explained in the earlier question, the Group is facing limited space issues, whereby the additional gastroenterologist lacks adequate space to operate. The Group primary challenge would be bed shortage issues, rather than the inability to attract skilled professionals.</p>
<p><b>11. The tumbling of share price of &gt;40% is due to the issues relating to the ambitious Proposed Acquisition and possible cash &amp; for the next 7 years with capital constraints that affect its dividend policy. The management also hasn't addressed the issues of conflict on interests especially in relation to its former CEO, the vendor &amp; landlord that related to this Proposed Acquisition. In addition, with this change of business model from light to heavy, how does it benefit the Group? Pls clarify.</b></p>	<p>The Company's dividend policy remains unaffected by capital constraints as observed in our previous two consecutive profitable quarters. Therefore, we can maintain the dividend pay-out.</p> <p>It is important to note that the expansion plan is before the joining of Mr Micheal as the Group's Chief Executive Officer. Therefore, there is no conflict of interest by Mr Micheal.</p>
<p><b>12. The Proposed Acquisition it is impediment for a young medical Group like Cengild to scale up fast &amp; subsequently affects it transfer listing to the Main Market. The share price decline 40% already indicates the value destruction. Also, this acquisition is from UOA Group which also the landlord of its current premise. It there a conflict of interest that the Company needs to address? Please clarify on this.</b></p>	<p>In order to facilitate the expansion plan, the Group must decide between leasing or acquiring the new building. The acquisition does not give rise to a conflict-of-interest situation, as it aligns with our objective of securing additional space.</p>
<p><b>Dividend</b></p>	
<p><b>13. Currently, the Company has a dividend payout ratio of at least 25% from its consolidated net profit attributable to the owners of the company, excluding exceptional items, for each financial year, after taking into account its financial performance, cash flow requirements and capital expenditure plans. With the Proposed Acquisition, how does it affect the dividend policy of the Company?</b></p>	<p>As explained earlier, the acquisition will not affect the Company's dividend policy.</p>



Revenue, Cost and Business Growth	
<p>14. The management stated that during the last AGM on 29 November 2023 that the demise of Prof. Dato' Dr. Goh as his patient were handled by gastroenterologist and hepatologists at the Company. It is not the case as the revenue of Q2 2024 has declined RM3 mil while the administration expenses have increased RM1.0 million. What is the plan of the management to increase its revenue base as it seems that the Group is facing stagnant revenue for the last few financial years, while the operating costs are increasing.</p>	<p>The revenue trajectory over recent years demonstrate growth rather than stagnation. Specifically in 4<sup>th</sup> Quarter for the financial year ended 2023, the revenue amounted to RM15.77million; Subsequently, during the 1<sup>st</sup> Quarter of financial year ending 2024, revenue increased to RM17.60 million, followed by RM16.05 million during 2<sup>nd</sup> quarter of financial year ending 2024. There was no evidence of decline in term of revenue.</p>
<p>15. The utmost priority is to focus on internal generation of cash flow which is lacking in the Group. Next, to implement cost-cutting measures as there is too much fat in the Group. Also, get the right people in the Group. The low share price due to poor management of the businesses will become an issue to raise funds via equity in the future for working capital and expansion purposes. Please relook into these measures.</p>	<p>The cash generated from operations during the 1<sup>st</sup> Quarter for financial year ending 2024 amounted to RM5.382 million; and RM9.795 million generated during the first half of financial year ending 2024.</p>
<p>16. What is the plan of the Group to increase its employee consultants? As the demise of the Late Emeritus Professor Dato' Dr. Goh Khean Lee has materially impacted its financial performance for the last few quarters. Moreover, is the Group facing with the inability to attract, hire and retain suitable medical candidates, that may negatively affect its business operations and future prospects.</p>	<p>There is a constraint on the numbers of doctors that can be hired, primarily due to the limited available space and beds. The passing of Professor Goh has not affected the overall volume of endoscopic procedures performed. However, there is a decline in surgical procedures eg bariatric procedure due to a new drug that can reduce weight in the market.</p> <p>As explained earlier, the Group primary challenge would be bed shortage issues, rather than the inability to attract skilled professionals.</p>
<p>17. What is the growth in terms of percentage and value of its corporate healthcare segment since its IPO, especially from the insurance companies and third-party administrator.</p>	<p>The percentage revenue contribution from the insurance and third-party administrations has increased by 5% to 8% since IPO.</p>

<p><b>18. Any cost-cutting or optimisation measures that have been implemented to improve the performance of the Group?</b></p>	<p>Management team meets on a regular basis to conduct comprehensive reviews and discuss both operational and financial performance, with the aim to enhance the Group's overall performance. Additionally, we are introducing initiatives to expand our range of sub-specialty services related to our specialists, along with diversifying with our medical services.</p>
<p><b>19. The Group needs ample of time to build up a track record as a public company. Its financials are still at infant phases with erratic after-tax earnings between RM1.5 mil - RM13.3 mil since FYE 2019. There is much to do for the management team to justify its value to the shareholders. While dividend payout ratio of at least 25% from its consolidated net profit is commendable but it is more important for the management team to deliver consistent &amp; growing top line and bottom line. Kindly comment on this.</b></p>	<p>The Group has witnessed a steady increase in both revenue and profit after tax over recent fiscal years. The profit after tax increasing from RM1.47 million for the financial year 2019 to RM3.95 million for year 2020 and further to RM10 million for year 2021. Despite listing expenses leading to a decline in profit after tax to RM9.4 million for year 2022, subsequent profit after tax reaches RM13.29 million for year 2023.</p>
<p><b>Utilisation</b></p>	
<p><b>20. What is the bed and OT utilisation capacity at Cengild Bangsar?</b></p>	<p>Occupancy rate for inpatient bed ranges from 65% to 90%, Day-care beds are currently operating at full capacity.</p>
<p><b>Employee Consultant</b></p>	
<p><b>21. During the IPO, the Group has 6 Employee Consultants, 5 Residence Consultants, 17 Visiting Consultants and 4 medical officers. Total 32 medical consultants/officer.</b></p> <p><b>As at the end of April 2024, the Group has a total of 48 medical consultants/officers. With the growth of the medical headcount, what is the impact to the top line and bottom-line going forward. Also, with the enlarged facilities as part of the Proposed Acquisition, how many medical consultants/officers are we expecting?</b></p>	<p>Patients in private medical centre pay the doctors by cash or through medical insurance. The medical centre acts as an intermediary, collecting payments on behalf of the doctors and subsequently pay-out to them. As such, more doctors would translate to more business.</p>

Share Price	
<p><b>22. The share price of the Company is declining to all time low upon the issuance of circular of the Proposed Acquisition &amp; fixing of EGM date. It is a barometer of lack of confidence on how the management can grow the business with the Proposed Acquisition &amp; turnaround its declining financial results. Kindly provide us a roadmap on the Group turnaround strategies.</b></p>	<p>The share price is beyond the control of management as the share price movement is market driven.</p> <p>There has been no indication of declining financial performance in the past two financial quarters. The Group aims to grow by expanding its range of sub-specialties and establishing new screening centre to broaden our revenue stream.</p>
Investor Relation	
<p><b>23. It is the fiduciary duties of the management to address all the warranted concerns to the shareholders, especially on this sceptical Proposed Acquisition. I have sent my queries a dozen of times but none of my queries was reverted. Moreover, none of the investor relations personnel addressed my queries. The Company has the worst investor relations in Bursa. What is the point of listing when you do not communicate and accountable to the public shareholders. Please relook on this.</b></p>	<p>You are encouraged to submit your questions directly to the acting Chief Executive Officer. Her contact information can be accessed on our official website.</p>
<p><b>24. Pls improve on the stakeholder engagement. It is poorly executed especially on the communication channels. No email to direct to the investor relations and none of your staff is responding to my queries. What is the point of the listing if you don't engage with the shareholders and fund analysts? As the contributor of capital, I demand these shortcomings to be rectified immediately. We do not want the company to engage us when you're in need of money only.</b></p>	<p>We value our shareholders' concerns and to address all questions raised to the fullest extent of our knowledge and capabilities.</p>
<p><b>25. Hope the Group will not cherry-pick on the questions raised &amp; address all the questions in the EGM. Please minute all the questions and concern raised by the shareholders. We took the liberty to ask, as the Group faced with many issues since its IPO. All the questions raised are warranted concerns. Please take note on this matter.</b></p>	<p>We have always practiced grouping similar questions together. The management acknowledges the suggestions provided and had added a submission page to receive investors' questions at any time. These questions are redirected to the acting Chief Executive Officer's email for consideration.</p>

<b>Management Personnel</b>	
<p><b>26. MICHEAL BONG ENN CHUNG has resigned as the Group CEO on 22 March 2024. The resignation is peculiar as it was abruptly done &amp; the announcement just stated to pursue personal interests. In the interim, the former CEO has re-joined as the acting CEO. Does it have to do with the ambitious Proposed Acquisition that is related to the UOA Group. Since he was a former CEO of the healthcare subsidiary of UOA Group. Please clarify on this.</b></p>	<p>Mr. Micheal Bong Enn Chung @ Micheal Wong Enn Chung's resignation was not abruptly done. He served a month's notice in accordance with the Company's policy. An announcement concerning his departure as Group CEO in accordance with Rule 9.19(14) of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad was made on his final day of service, rather than upon the initial tendering of his resignation to the company.</p>
<p><b>27. Coincidentally the Group CEO, Michael Bong resigned with immediate effect a few days from the announcement of EGM pertaining to the Proposed Acquisition. Prior to his service in Cengild, he was the CEO of the Medical &amp; Healthcare of UOA Development Bhd &amp; the vendor of the Proposed Acquisition is UOA. As the Proposed Acquisition is highly contentious and sceptical, was his resignation has something to do with a conflict of interest pertaining this deal? Pls clarify on this.</b></p>	
<b>Data Breach</b>	
<p><b>28. Have the data breach issue that may have leaked patient data been resolved? How did this issue affect its business?</b></p>	<p>The data breach did not affect the operations of the business. In fact, the issues had been addressed within a few hours. We have upgraded our anti-virus software and implemented measures to fortify and bolster our informational technology infrastructure.</p>
<p><b>29. Have the Chairman of Audit Committee provided the recommendations pertaining to the data breaches &amp; sustainability of its business model. Have these recommendations been implemented by the management team and the results in 2023.</b></p>	<p>Yes, the Chairman of Audit Committee provided the recommendations pertaining to the data breaches and sustainability of its business model and it has been implemented.</p>

<b>Risk Management</b>	
<b>30. Since Cengild has short operating history, its medical centre may not be well known to the general public. any adverse events i.e. data breaches, failure of its medical equipment or loss of consultants may disrupt its operations and prevent the company from providing quality healthcare services. What are the risk management policies taken to mitigate these risks? What is the churn rate of its patients since the incurrence of data breaches?</b>	Data breach did not affect daily operations. More importantly, our medical equipment remains well maintained, each covered by a maintenance contract, ensuring prompt response upon detection of any issues. Notably, none of our medical equipment was compromised by the data breach. As a responsible public listed company, we decided to disclose this incident to the public.
<b>Door Gift</b>	
<b>31. Kindly consider distributing door gift to delight the shareholders.</b>	We practice a no-gift policy. We believe in rewarding all our shareholders equally and meaningfully through distribution of dividend.
<b>Live Questions</b>	
<b>32. Will the current acquisition affect your company profitability?</b>	The Group outlined plans for expansion, which required additional space. To accommodate this need, the Group must acquire or lease new premises. Acquiring would be cheaper as compared to leasing in the long term. However, it is important to note that completion of the new building is not anticipated until 2026 or 2027.
<b>33. Can you please explain why patients will choose your medical center over public hospital, which is much more cheaper, and other private hospitals?</b>	Public hospitals provide free-of-charge services, while we were usually referred by another hospital or private medical centre where specialists are required.
<b>34. May I know what your capacity utilization rate in the current medical center is?</b>	As explained earlier, the operating theatre utilisation rate for the first half of the year 2024 was approximately 60-65%. Presently, our medical centre comprises 20 in-patient beds and 16 day-care beds.
<b>35. This coming quarter will expect how much profit?</b>	The company will release announcement to Bursa Malaysia Securities Berhad on the third quarter financial results by end of this month.

**CENGILD MEDICAL BERHAD**

(202101004143)

**Extraordinary General Meeting**TIH Online website at <https://tih.online>

On 13-May-2024 at 03:00PM

**Result On Voting By Poll**

Resolution(s)	Vote For				Vote Against				Total Votes			
	No of Units	%	No of P/S	%	No of Units	%	No of P/S	%	No of Units	%	No of P/S	%
Ordinary Resolution 1	403,965,911	99.8718	67	78.8235	518,556	0.1282	18	21.1765	404,484,467	100.0000	85	100.0000
Ordinary Resolution 2	403,975,911	99.8743	68	80.0000	508,556	0.1257	17	20.0000	404,484,467	100.0000	85	100.0000



CENGILD MEDICAL BERHAD (202101004143) (1404442-P)  
MINUTES OF THE EXTRAORDINARY GENERAL MEETING HELD ON 13 MAY 2024

---

-2-

Resolution(s)	Pre-determined Abstain *		Abstain / Spoilt #	
	No of Units	No of P/S	No of Units	No of P/S
Ordinary Resolution 1	0	0	5,000	1
Ordinary Resolution 2	0	0	5,000	1

\* These votes refer to holders who have pre-determined abstain from voting in proxy forms or holders refrained from voting due to conflict of interest.

# These refer to:

- 1) Holders who have chosen not to vote (e-voting) or
- 2) Abstain / Spoilt votes as reflected in poll slips (poll slip voting)

